BP

Ben Price

Percheron Therapeutics Limited | Non-Executive Director
Dr Price is an experienced biotech executive and entrepreneur with expertise across clinical asset investment strategy, evaluation, financing and execution. Additional leadership experience includes R&D, Medical, and strategic corporate functions. Between November 2021 and January 2023, he served as Neurobo Pharmaceuticals, President and CEO. Prior to joining Neurobo, Gil was Chief Medical Officer of ProPharma Group, a global industry leader in comprehensive compliance services that span the entire lifecycle of pharmaceuticals, biologics, and devices. Gil was previously responsible for the strategic and tactical management of all business at Drug Safety Solutions. Over the years Gil has served on multiple corporate boards, including public, private and not-for-profit. His recent experience, Rexahn Pharmaceuticals, Inc. (NYSE American: RNN) he served on Compensation, Governance, and Business Development. He is a Member of the Governance Committee.

Company and Role

Company
Title
Tenure
Since
PER
PER
Percheron Therapeutics Limited
  • Non-Executive Director
4yrs, 9mthOct 2021

Holdings

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
PER
PER
Percheron Therapeutics Limited
22/12/257,999,805N/A3,000,000N/A
ANP
ANP
26/09/23999,805N/A1,000,000N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
PER
PER
Percheron Therapeutics Limited
22/12/25
Buy
2,000,000$0.009$17,220On-market trade
PER
PER
Percheron Therapeutics Limited
31/03/25
Buy
5,000,000$0.012$58,121On-market trade
PER
PER
Percheron Therapeutics Limited
18/03/25
Expiry
1,000,000$0.010$10,000Options expired
PER
PER
Percheron Therapeutics Limited
25/11/24
Issued
3,000,000$0.063$189,000Issue of options
PER
PER
Percheron Therapeutics Limited
26/09/23
Buy
400,000$0.071$28,400On-market trade